2. Search Result
Search Result
Pathways Recommended: TGF-beta/Smad
Results for "

CD8 beta

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

3

Peptides

1

Inhibitory Antibodies

6

Recombinant Proteins

1

Antibodies

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2511
    Insulin β Chain Peptide (15-23)

    		Transmembrane Glycoprotein Metabolic Disease
    Insulin β Chain Peptide (15-23) is one of the earliest antigenic epitopes to which CD8 T-cells respond .
    Insulin β Chain Peptide (15-23)
  • HY-P5189A
    His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA

    		Endogenous Metabolite Cholinesterase (ChE) Others
    His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA, is a growth hormone releasing peptide, as well as a metabolite of GHRP-1. GHRP-1, or Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2, has the effect of promoting the release of growth hormone (GH). GHRP-1 increases GH release and increases [Ca2+]i levels in static monolayer cells of rat pituitary gland, but does not affect cAMP levels .
    His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA
  • HY-RS02276
    CD8B Human Pre-designed siRNA Set A

    LY3; P37; LEU2; LYT3; Ly-3; CD8B1; CD8beta

    		 Small Interfering RNA (siRNA) Others

    CD8B Human Pre-designed siRNA Set A contains three designed siRNAs for CD8B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD8B Human Pre-designed siRNA Set A
    CD8B Human Pre-designed siRNA Set A
  • HY-171331
    AB-3PRGD2

    		PD-1/PD-L1 Integrin Cancer
    AB-3PRGD2 is a radiotherapeutic agent targeting integrin αvβ3. AB-3PRGD2 shows improved tumor uptake and prolonged tumor retention, leading to significantly enhanced tumor growth suppression. AB-3PRGD2 can remodel the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8 + T cells .
    AB-3PRGD2
  • HY-172934
    FGT-4

    		Toll-like Receptor (TLR) NO Synthase PROTACs Inflammation/Immunology Cancer
    FGT-4 is a folate receptor β (FR-β) targeting chimeric molecule. FGT-4 is a TLR7 agonist. FGT-4 facilitates the secretion of iNOS and proinflammatory cytokine IL-6 associated with M1 macrophages and enhances the proliferation of cytotoxic CD8 + T cells. FGT-4 has anti-tumor activity in the 4T1 breast cancer mouse model. FGT-4 can be used for the study of cancer immunity. (Pink: target protein TLR7/8 agonist 1 ligand (HY-103698); black: linker (HY-172936); blue: FR-β ligand (HY-172935)) .
    FGT-4
  • HY-169859
    EP4 receptor antagonist 7

    		Prostaglandin Receptor Interleukin Related Inflammation/Immunology Cancer
    EP4 receptor antagonist 7 (Compound 14) is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 with an IC50 value of 1.1 nM. EP4 receptor antagonist 7 inhibits PGE2-induced β-arrestin recruitment in HEK293 cells with an IC50 value of 0.9 nM. EP4 receptor antagonist 7 decreases PGE2-induced expression of mRNA encoding IL-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C) motif ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase-1 (Arg1), in RAW 264.7 macrophages. EP4 receptor antagonist 7 combined with an anti-PD-1 antibody inhibits tumor growth and increases infiltration of CD 8+ T cells into tumors in a CT26 murine colon cancer model .
    EP4 receptor antagonist 7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: